nodes	percent_of_prediction	percent_of_DWPC	metapath
Carvedilol—VEGFA—ovarian cancer	0.33	0.796	CbGaD
Carvedilol—ABCB1—ovarian cancer	0.0848	0.204	CbGaD
Carvedilol—XDH—Carboplatin—ovarian cancer	0.0749	0.33	CbGbCtD
Carvedilol—XDH—Doxorubicin—ovarian cancer	0.0429	0.189	CbGbCtD
Carvedilol—ABCB1—Topotecan—ovarian cancer	0.0183	0.0808	CbGbCtD
Carvedilol—ABCB1—Vinorelbine—ovarian cancer	0.0129	0.0569	CbGbCtD
Carvedilol—CYP2D6—Vinorelbine—ovarian cancer	0.0122	0.0536	CbGbCtD
Carvedilol—CYP3A4—Topotecan—ovarian cancer	0.011	0.0484	CbGbCtD
Carvedilol—GJA1—ovarian follicle—ovarian cancer	0.00935	0.0859	CbGeAlD
Carvedilol—CYP2C9—Paclitaxel—ovarian cancer	0.00934	0.0412	CbGbCtD
Carvedilol—ABCB1—Paclitaxel—ovarian cancer	0.00907	0.04	CbGbCtD
Carvedilol—SELE—vein—ovarian cancer	0.00778	0.0715	CbGeAlD
Carvedilol—CYP3A4—Vinorelbine—ovarian cancer	0.00773	0.0341	CbGbCtD
Carvedilol—VCAM1—vein—ovarian cancer	0.00716	0.0657	CbGeAlD
Carvedilol—ABCB1—Docetaxel—ovarian cancer	0.00655	0.0289	CbGbCtD
Carvedilol—CYP3A4—Paclitaxel—ovarian cancer	0.00543	0.024	CbGbCtD
Carvedilol—ABCB1—Doxorubicin—ovarian cancer	0.00489	0.0216	CbGbCtD
Carvedilol—CYP2D6—Doxorubicin—ovarian cancer	0.0046	0.0203	CbGbCtD
Carvedilol—GJA1—oviduct—ovarian cancer	0.00411	0.0377	CbGeAlD
Carvedilol—CYP3A4—Docetaxel—ovarian cancer	0.00393	0.0173	CbGbCtD
Carvedilol—CYP3A4—Doxorubicin—ovarian cancer	0.00293	0.0129	CbGbCtD
Carvedilol—NPPB—myometrium—ovarian cancer	0.00227	0.0208	CbGeAlD
Carvedilol—SELE—myometrium—ovarian cancer	0.00153	0.0141	CbGeAlD
Carvedilol—VCAM1—myometrium—ovarian cancer	0.00141	0.0129	CbGeAlD
Carvedilol—HIF1A—myometrium—ovarian cancer	0.00136	0.0124	CbGeAlD
Carvedilol—GJA1—myometrium—ovarian cancer	0.00131	0.0121	CbGeAlD
Carvedilol—HIF1A—embryo—ovarian cancer	0.0013	0.012	CbGeAlD
Carvedilol—GJA1—embryo—ovarian cancer	0.00126	0.0116	CbGeAlD
Carvedilol—SELE—epithelium—ovarian cancer	0.0012	0.011	CbGeAlD
Carvedilol—SELE—uterine cervix—ovarian cancer	0.00119	0.0109	CbGeAlD
Carvedilol—NDUFC2—myometrium—ovarian cancer	0.00114	0.0105	CbGeAlD
Carvedilol—VCAM1—epithelium—ovarian cancer	0.00111	0.0102	CbGeAlD
Carvedilol—VCAM1—uterine cervix—ovarian cancer	0.0011	0.0101	CbGeAlD
Carvedilol—HIF1A—epithelium—ovarian cancer	0.00106	0.00977	CbGeAlD
Carvedilol—HIF1A—uterine cervix—ovarian cancer	0.00105	0.00968	CbGeAlD
Carvedilol—VCAM1—decidua—ovarian cancer	0.00104	0.00959	CbGeAlD
Carvedilol—VEGFA—myometrium—ovarian cancer	0.00104	0.00953	CbGeAlD
Carvedilol—GJA1—epithelium—ovarian cancer	0.00103	0.00948	CbGeAlD
Carvedilol—GJA1—uterine cervix—ovarian cancer	0.00102	0.00939	CbGeAlD
Carvedilol—HIF1A—decidua—ovarian cancer	0.001	0.00923	CbGeAlD
Carvedilol—SELE—uterus—ovarian cancer	0.000993	0.00912	CbGeAlD
Carvedilol—VCAM1—endometrium—ovarian cancer	0.000991	0.0091	CbGeAlD
Carvedilol—GJA1—decidua—ovarian cancer	0.000975	0.00895	CbGeAlD
Carvedilol—HIF1A—endometrium—ovarian cancer	0.000954	0.00876	CbGeAlD
Carvedilol—GJA1—endometrium—ovarian cancer	0.000925	0.0085	CbGeAlD
Carvedilol—VCAM1—uterus—ovarian cancer	0.000914	0.00839	CbGeAlD
Carvedilol—NDUFC2—epithelium—ovarian cancer	0.000898	0.00825	CbGeAlD
Carvedilol—SELE—female reproductive system—ovarian cancer	0.000893	0.0082	CbGeAlD
Carvedilol—NDUFC2—uterine cervix—ovarian cancer	0.000891	0.00818	CbGeAlD
Carvedilol—HIF1A—gonad—ovarian cancer	0.000885	0.00812	CbGeAlD
Carvedilol—HIF1A—uterus—ovarian cancer	0.000879	0.00807	CbGeAlD
Carvedilol—PTGS1—oviduct—ovarian cancer	0.000872	0.00801	CbGeAlD
Carvedilol—GJA1—gonad—ovarian cancer	0.000858	0.00788	CbGeAlD
Carvedilol—GJA1—uterus—ovarian cancer	0.000853	0.00783	CbGeAlD
Carvedilol—NDUFC2—decidua—ovarian cancer	0.000848	0.00779	CbGeAlD
Carvedilol—VCAM1—female reproductive system—ovarian cancer	0.000821	0.00754	CbGeAlD
Carvedilol—SELE—female gonad—ovarian cancer	0.000812	0.00746	CbGeAlD
Carvedilol—VEGFA—uterine cervix—ovarian cancer	0.000808	0.00742	CbGeAlD
Carvedilol—SELE—vagina—ovarian cancer	0.000808	0.00742	CbGeAlD
Carvedilol—NDUFC2—endometrium—ovarian cancer	0.000805	0.0074	CbGeAlD
Carvedilol—HIF1A—female reproductive system—ovarian cancer	0.00079	0.00726	CbGeAlD
Carvedilol—VCAM1—bone marrow—ovarian cancer	0.000775	0.00712	CbGeAlD
Carvedilol—VEGFA—decidua—ovarian cancer	0.00077	0.00707	CbGeAlD
Carvedilol—GJA1—female reproductive system—ovarian cancer	0.000767	0.00704	CbGeAlD
Carvedilol—VCAM1—female gonad—ovarian cancer	0.000747	0.00686	CbGeAlD
Carvedilol—NDUFC2—gonad—ovarian cancer	0.000747	0.00686	CbGeAlD
Carvedilol—HIF1A—bone marrow—ovarian cancer	0.000746	0.00685	CbGeAlD
Carvedilol—VCAM1—vagina—ovarian cancer	0.000743	0.00682	CbGeAlD
Carvedilol—NDUFC2—uterus—ovarian cancer	0.000742	0.00682	CbGeAlD
Carvedilol—VEGFA—endometrium—ovarian cancer	0.000731	0.00671	CbGeAlD
Carvedilol—GJA1—bone marrow—ovarian cancer	0.000724	0.00665	CbGeAlD
Carvedilol—SELE—testis—ovarian cancer	0.000721	0.00662	CbGeAlD
Carvedilol—XDH—uterine cervix—ovarian cancer	0.000719	0.0066	CbGeAlD
Carvedilol—HIF1A—female gonad—ovarian cancer	0.000719	0.0066	CbGeAlD
Carvedilol—HIF1A—vagina—ovarian cancer	0.000715	0.00656	CbGeAlD
Carvedilol—ADRB3—female reproductive system—ovarian cancer	0.000702	0.00645	CbGeAlD
Carvedilol—GJA1—female gonad—ovarian cancer	0.000697	0.0064	CbGeAlD
Carvedilol—GJA1—vagina—ovarian cancer	0.000693	0.00637	CbGeAlD
Carvedilol—VEGFA—uterus—ovarian cancer	0.000673	0.00618	CbGeAlD
Carvedilol—NDUFC2—female reproductive system—ovarian cancer	0.000667	0.00613	CbGeAlD
Carvedilol—VCAM1—testis—ovarian cancer	0.000663	0.00609	CbGeAlD
Carvedilol—XDH—endometrium—ovarian cancer	0.00065	0.00597	CbGeAlD
Carvedilol—ADRB3—female gonad—ovarian cancer	0.000639	0.00587	CbGeAlD
Carvedilol—HIF1A—testis—ovarian cancer	0.000638	0.00586	CbGeAlD
Carvedilol—NDUFC2—bone marrow—ovarian cancer	0.00063	0.00578	CbGeAlD
Carvedilol—GJA1—testis—ovarian cancer	0.000619	0.00568	CbGeAlD
Carvedilol—NDUFC2—female gonad—ovarian cancer	0.000607	0.00558	CbGeAlD
Carvedilol—NDUFC2—vagina—ovarian cancer	0.000603	0.00554	CbGeAlD
Carvedilol—VEGFA—bone marrow—ovarian cancer	0.000571	0.00525	CbGeAlD
Carvedilol—VEGFA—female gonad—ovarian cancer	0.000551	0.00506	CbGeAlD
Carvedilol—VEGFA—vagina—ovarian cancer	0.000547	0.00503	CbGeAlD
Carvedilol—XDH—female reproductive system—ovarian cancer	0.000539	0.00495	CbGeAlD
Carvedilol—NDUFC2—testis—ovarian cancer	0.000538	0.00494	CbGeAlD
Carvedilol—ADRA1D—epithelium—ovarian cancer	0.000532	0.00489	CbGeAlD
Carvedilol—SELE—lymph node—ovarian cancer	0.000522	0.0048	CbGeAlD
Carvedilol—VEGFA—testis—ovarian cancer	0.000488	0.00449	CbGeAlD
Carvedilol—XDH—vagina—ovarian cancer	0.000487	0.00447	CbGeAlD
Carvedilol—VCAM1—lymph node—ovarian cancer	0.00048	0.00441	CbGeAlD
Carvedilol—HIF1A—lymph node—ovarian cancer	0.000462	0.00424	CbGeAlD
Carvedilol—GJA1—lymph node—ovarian cancer	0.000448	0.00412	CbGeAlD
Carvedilol—ADRA1D—female reproductive system—ovarian cancer	0.000395	0.00363	CbGeAlD
Carvedilol—NDUFC2—lymph node—ovarian cancer	0.00039	0.00358	CbGeAlD
Carvedilol—KCNH2—myometrium—ovarian cancer	0.000376	0.00345	CbGeAlD
Carvedilol—ADRA2C—myometrium—ovarian cancer	0.000371	0.00341	CbGeAlD
Carvedilol—VEGFA—lymph node—ovarian cancer	0.000354	0.00325	CbGeAlD
Carvedilol—ADRA1A—epithelium—ovarian cancer	0.000306	0.00281	CbGeAlD
Carvedilol—ADRA2A—myometrium—ovarian cancer	0.000296	0.00272	CbGeAlD
Carvedilol—KCNH2—uterine cervix—ovarian cancer	0.000293	0.00269	CbGeAlD
Carvedilol—ADRA2C—uterine cervix—ovarian cancer	0.000289	0.00265	CbGeAlD
Carvedilol—ADRB1—female reproductive system—ovarian cancer	0.000287	0.00264	CbGeAlD
Carvedilol—ADRA2C—decidua—ovarian cancer	0.000275	0.00253	CbGeAlD
Carvedilol—KCNH2—endometrium—ovarian cancer	0.000265	0.00243	CbGeAlD
Carvedilol—ADRA2C—endometrium—ovarian cancer	0.000261	0.0024	CbGeAlD
Carvedilol—CYP1A1—epithelium—ovarian cancer	0.000249	0.00229	CbGeAlD
Carvedilol—CYP1A1—uterine cervix—ovarian cancer	0.000247	0.00227	CbGeAlD
Carvedilol—KCNH2—uterus—ovarian cancer	0.000244	0.00224	CbGeAlD
Carvedilol—ADRA2C—uterus—ovarian cancer	0.000241	0.00221	CbGeAlD
Carvedilol—ADRA2A—uterine cervix—ovarian cancer	0.00023	0.00212	CbGeAlD
Carvedilol—ADRA2A—decidua—ovarian cancer	0.00022	0.00202	CbGeAlD
Carvedilol—KCNH2—female reproductive system—ovarian cancer	0.000219	0.00201	CbGeAlD
Carvedilol—PTGS1—epithelium—ovarian cancer	0.000219	0.00201	CbGeAlD
Carvedilol—PTGS1—uterine cervix—ovarian cancer	0.000217	0.00199	CbGeAlD
Carvedilol—ADRA2A—endometrium—ovarian cancer	0.000208	0.00191	CbGeAlD
Carvedilol—KCNH2—bone marrow—ovarian cancer	0.000207	0.0019	CbGeAlD
Carvedilol—CYP1A1—uterus—ovarian cancer	0.000206	0.00189	CbGeAlD
Carvedilol—KCNH2—female gonad—ovarian cancer	0.0002	0.00183	CbGeAlD
Carvedilol—KCNH2—vagina—ovarian cancer	0.000198	0.00182	CbGeAlD
Carvedilol—ADRA2C—female gonad—ovarian cancer	0.000197	0.00181	CbGeAlD
Carvedilol—PTGS1—endometrium—ovarian cancer	0.000196	0.0018	CbGeAlD
Carvedilol—ADRA2C—vagina—ovarian cancer	0.000196	0.0018	CbGeAlD
Carvedilol—ADRA2A—gonad—ovarian cancer	0.000193	0.00178	CbGeAlD
Carvedilol—ADRA2A—uterus—ovarian cancer	0.000192	0.00176	CbGeAlD
Carvedilol—CYP1A1—female reproductive system—ovarian cancer	0.000185	0.0017	CbGeAlD
Carvedilol—PTGS1—uterus—ovarian cancer	0.000181	0.00166	CbGeAlD
Carvedilol—CYP2C9—female reproductive system—ovarian cancer	0.000178	0.00164	CbGeAlD
Carvedilol—KCNH2—testis—ovarian cancer	0.000177	0.00163	CbGeAlD
Carvedilol—ADRA2C—testis—ovarian cancer	0.000175	0.0016	CbGeAlD
Carvedilol—ADRA2A—female reproductive system—ovarian cancer	0.000173	0.00159	CbGeAlD
Carvedilol—CYP2E1—female reproductive system—ovarian cancer	0.000169	0.00155	CbGeAlD
Carvedilol—CYP1A1—female gonad—ovarian cancer	0.000169	0.00155	CbGeAlD
Carvedilol—CYP1A1—vagina—ovarian cancer	0.000168	0.00154	CbGeAlD
Carvedilol—ABCB1—myometrium—ovarian cancer	0.000165	0.00152	CbGeAlD
Carvedilol—PTGS1—female reproductive system—ovarian cancer	0.000163	0.00149	CbGeAlD
Carvedilol—ABCB1—embryo—ovarian cancer	0.000159	0.00146	CbGeAlD
Carvedilol—ADRA2A—female gonad—ovarian cancer	0.000157	0.00144	CbGeAlD
Carvedilol—ADRA2A—vagina—ovarian cancer	0.000156	0.00143	CbGeAlD
Carvedilol—PTGS1—female gonad—ovarian cancer	0.000148	0.00136	CbGeAlD
Carvedilol—PTGS1—vagina—ovarian cancer	0.000147	0.00135	CbGeAlD
Carvedilol—ADRA2A—testis—ovarian cancer	0.000139	0.00128	CbGeAlD
Carvedilol—CYP2E1—testis—ovarian cancer	0.000136	0.00125	CbGeAlD
Carvedilol—CYP3A4—female reproductive system—ovarian cancer	0.000136	0.00125	CbGeAlD
Carvedilol—CYP2D6—female reproductive system—ovarian cancer	0.000134	0.00123	CbGeAlD
Carvedilol—PTGS1—testis—ovarian cancer	0.000131	0.00121	CbGeAlD
Carvedilol—ABCB1—epithelium—ovarian cancer	0.00013	0.00119	CbGeAlD
Carvedilol—ABCB1—uterine cervix—ovarian cancer	0.000128	0.00118	CbGeAlD
Carvedilol—KCNH2—lymph node—ovarian cancer	0.000128	0.00118	CbGeAlD
Carvedilol—ADRA2C—lymph node—ovarian cancer	0.000127	0.00116	CbGeAlD
Carvedilol—ABCB1—decidua—ovarian cancer	0.000122	0.00112	CbGeAlD
Carvedilol—CYP2D6—female gonad—ovarian cancer	0.000122	0.00112	CbGeAlD
Carvedilol—ABCB1—endometrium—ovarian cancer	0.000116	0.00107	CbGeAlD
Carvedilol—CYP1A1—lymph node—ovarian cancer	0.000108	0.000995	CbGeAlD
Carvedilol—CYP2D6—testis—ovarian cancer	0.000108	0.000991	CbGeAlD
Carvedilol—ABCB1—gonad—ovarian cancer	0.000108	0.000989	CbGeAlD
Carvedilol—ABCB1—uterus—ovarian cancer	0.000107	0.000983	CbGeAlD
Carvedilol—ADRA2A—lymph node—ovarian cancer	0.000101	0.000928	CbGeAlD
Carvedilol—ABCB1—female reproductive system—ovarian cancer	9.62e-05	0.000884	CbGeAlD
Carvedilol—PTGS1—lymph node—ovarian cancer	9.52e-05	0.000874	CbGeAlD
Carvedilol—ABCB1—bone marrow—ovarian cancer	9.08e-05	0.000834	CbGeAlD
Carvedilol—ABCB1—female gonad—ovarian cancer	8.76e-05	0.000804	CbGeAlD
Carvedilol—ABCB1—vagina—ovarian cancer	8.7e-05	0.000799	CbGeAlD
Carvedilol—Photosensitivity reaction—Epirubicin—ovarian cancer	8.49e-05	0.000603	CcSEcCtD
Carvedilol—Weight increased—Epirubicin—ovarian cancer	8.47e-05	0.000601	CcSEcCtD
Carvedilol—Loss of consciousness—Docetaxel—ovarian cancer	8.45e-05	0.0006	CcSEcCtD
Carvedilol—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	8.43e-05	0.000599	CcSEcCtD
Carvedilol—Weight decreased—Epirubicin—ovarian cancer	8.42e-05	0.000598	CcSEcCtD
Carvedilol—Hyperglycaemia—Epirubicin—ovarian cancer	8.39e-05	0.000596	CcSEcCtD
Carvedilol—Cough—Docetaxel—ovarian cancer	8.39e-05	0.000596	CcSEcCtD
Carvedilol—Angina pectoris—Doxorubicin—ovarian cancer	8.38e-05	0.000596	CcSEcCtD
Carvedilol—Insomnia—Paclitaxel—ovarian cancer	8.37e-05	0.000594	CcSEcCtD
Carvedilol—Pneumonia—Epirubicin—ovarian cancer	8.34e-05	0.000593	CcSEcCtD
Carvedilol—Convulsion—Docetaxel—ovarian cancer	8.33e-05	0.000591	CcSEcCtD
Carvedilol—Paraesthesia—Paclitaxel—ovarian cancer	8.31e-05	0.00059	CcSEcCtD
Carvedilol—Hypertension—Docetaxel—ovarian cancer	8.3e-05	0.000589	CcSEcCtD
Carvedilol—Bronchitis—Doxorubicin—ovarian cancer	8.28e-05	0.000588	CcSEcCtD
Carvedilol—Dyspnoea—Paclitaxel—ovarian cancer	8.25e-05	0.000586	CcSEcCtD
Carvedilol—Somnolence—Paclitaxel—ovarian cancer	8.23e-05	0.000584	CcSEcCtD
Carvedilol—Stevens-Johnson syndrome—Epirubicin—ovarian cancer	8.22e-05	0.000584	CcSEcCtD
Carvedilol—Arthralgia—Docetaxel—ovarian cancer	8.18e-05	0.000581	CcSEcCtD
Carvedilol—Myalgia—Docetaxel—ovarian cancer	8.18e-05	0.000581	CcSEcCtD
Carvedilol—Chest pain—Docetaxel—ovarian cancer	8.18e-05	0.000581	CcSEcCtD
Carvedilol—Pancytopenia—Doxorubicin—ovarian cancer	8.17e-05	0.000581	CcSEcCtD
Carvedilol—Nausea—Vinorelbine—ovarian cancer	8.17e-05	0.00058	CcSEcCtD
Carvedilol—Renal failure—Epirubicin—ovarian cancer	8.15e-05	0.000579	CcSEcCtD
Carvedilol—Dyspepsia—Paclitaxel—ovarian cancer	8.15e-05	0.000579	CcSEcCtD
Carvedilol—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	8.13e-05	0.000577	CcSEcCtD
Carvedilol—Urinary tract infection—Epirubicin—ovarian cancer	8.06e-05	0.000573	CcSEcCtD
Carvedilol—Decreased appetite—Paclitaxel—ovarian cancer	8.04e-05	0.000571	CcSEcCtD
Carvedilol—Dry mouth—Docetaxel—ovarian cancer	8e-05	0.000568	CcSEcCtD
Carvedilol—Upper respiratory tract infection—Doxorubicin—ovarian cancer	8e-05	0.000568	CcSEcCtD
Carvedilol—Gastrointestinal disorder—Paclitaxel—ovarian cancer	7.99e-05	0.000567	CcSEcCtD
Carvedilol—Fatigue—Paclitaxel—ovarian cancer	7.98e-05	0.000567	CcSEcCtD
Carvedilol—Pollakiuria—Doxorubicin—ovarian cancer	7.95e-05	0.000565	CcSEcCtD
Carvedilol—Constipation—Paclitaxel—ovarian cancer	7.91e-05	0.000562	CcSEcCtD
Carvedilol—Pain—Paclitaxel—ovarian cancer	7.91e-05	0.000562	CcSEcCtD
Carvedilol—Haematuria—Epirubicin—ovarian cancer	7.91e-05	0.000562	CcSEcCtD
Carvedilol—Confusional state—Docetaxel—ovarian cancer	7.91e-05	0.000562	CcSEcCtD
Carvedilol—Photosensitivity reaction—Doxorubicin—ovarian cancer	7.86e-05	0.000558	CcSEcCtD
Carvedilol—Anaphylactic shock—Docetaxel—ovarian cancer	7.84e-05	0.000557	CcSEcCtD
Carvedilol—Oedema—Docetaxel—ovarian cancer	7.84e-05	0.000557	CcSEcCtD
Carvedilol—Weight increased—Doxorubicin—ovarian cancer	7.83e-05	0.000556	CcSEcCtD
Carvedilol—Infection—Docetaxel—ovarian cancer	7.79e-05	0.000553	CcSEcCtD
Carvedilol—Weight decreased—Doxorubicin—ovarian cancer	7.79e-05	0.000553	CcSEcCtD
Carvedilol—Sinusitis—Epirubicin—ovarian cancer	7.78e-05	0.000553	CcSEcCtD
Carvedilol—ABCB1—testis—ovarian cancer	7.77e-05	0.000713	CbGeAlD
Carvedilol—Hyperglycaemia—Doxorubicin—ovarian cancer	7.76e-05	0.000552	CcSEcCtD
Carvedilol—Pneumonia—Doxorubicin—ovarian cancer	7.72e-05	0.000548	CcSEcCtD
Carvedilol—Shock—Docetaxel—ovarian cancer	7.72e-05	0.000548	CcSEcCtD
Carvedilol—Thrombocytopenia—Docetaxel—ovarian cancer	7.68e-05	0.000545	CcSEcCtD
Carvedilol—Tachycardia—Docetaxel—ovarian cancer	7.65e-05	0.000544	CcSEcCtD
Carvedilol—Feeling abnormal—Paclitaxel—ovarian cancer	7.63e-05	0.000542	CcSEcCtD
Carvedilol—Skin disorder—Docetaxel—ovarian cancer	7.62e-05	0.000541	CcSEcCtD
Carvedilol—Stevens-Johnson syndrome—Doxorubicin—ovarian cancer	7.61e-05	0.00054	CcSEcCtD
Carvedilol—Bradycardia—Epirubicin—ovarian cancer	7.58e-05	0.000538	CcSEcCtD
Carvedilol—Gastrointestinal pain—Paclitaxel—ovarian cancer	7.57e-05	0.000537	CcSEcCtD
Carvedilol—Renal failure—Doxorubicin—ovarian cancer	7.54e-05	0.000536	CcSEcCtD
Carvedilol—Haemoglobin—Epirubicin—ovarian cancer	7.48e-05	0.000532	CcSEcCtD
Carvedilol—Anorexia—Docetaxel—ovarian cancer	7.48e-05	0.000531	CcSEcCtD
Carvedilol—Rhinitis—Epirubicin—ovarian cancer	7.47e-05	0.00053	CcSEcCtD
Carvedilol—Urinary tract infection—Doxorubicin—ovarian cancer	7.46e-05	0.00053	CcSEcCtD
Carvedilol—Haemorrhage—Epirubicin—ovarian cancer	7.45e-05	0.000529	CcSEcCtD
Carvedilol—Hypoaesthesia—Epirubicin—ovarian cancer	7.41e-05	0.000526	CcSEcCtD
Carvedilol—Pharyngitis—Epirubicin—ovarian cancer	7.39e-05	0.000525	CcSEcCtD
Carvedilol—Urinary tract disorder—Epirubicin—ovarian cancer	7.35e-05	0.000522	CcSEcCtD
Carvedilol—Urticaria—Paclitaxel—ovarian cancer	7.35e-05	0.000522	CcSEcCtD
Carvedilol—Oedema peripheral—Epirubicin—ovarian cancer	7.34e-05	0.000521	CcSEcCtD
Carvedilol—Hypotension—Docetaxel—ovarian cancer	7.33e-05	0.000521	CcSEcCtD
Carvedilol—Haematuria—Doxorubicin—ovarian cancer	7.32e-05	0.00052	CcSEcCtD
Carvedilol—Body temperature increased—Paclitaxel—ovarian cancer	7.31e-05	0.00052	CcSEcCtD
Carvedilol—Abdominal pain—Paclitaxel—ovarian cancer	7.31e-05	0.00052	CcSEcCtD
Carvedilol—Urethral disorder—Epirubicin—ovarian cancer	7.3e-05	0.000518	CcSEcCtD
Carvedilol—Sinusitis—Doxorubicin—ovarian cancer	7.2e-05	0.000511	CcSEcCtD
Carvedilol—Visual impairment—Epirubicin—ovarian cancer	7.18e-05	0.00051	CcSEcCtD
Carvedilol—Musculoskeletal discomfort—Docetaxel—ovarian cancer	7.15e-05	0.000508	CcSEcCtD
Carvedilol—Insomnia—Docetaxel—ovarian cancer	7.09e-05	0.000504	CcSEcCtD
Carvedilol—Paraesthesia—Docetaxel—ovarian cancer	7.04e-05	0.0005	CcSEcCtD
Carvedilol—Erythema multiforme—Epirubicin—ovarian cancer	7.04e-05	0.0005	CcSEcCtD
Carvedilol—Bradycardia—Doxorubicin—ovarian cancer	7.01e-05	0.000498	CcSEcCtD
Carvedilol—Dyspnoea—Docetaxel—ovarian cancer	6.99e-05	0.000497	CcSEcCtD
Carvedilol—Somnolence—Docetaxel—ovarian cancer	6.97e-05	0.000495	CcSEcCtD
Carvedilol—Tinnitus—Epirubicin—ovarian cancer	6.94e-05	0.000493	CcSEcCtD
Carvedilol—Haemoglobin—Doxorubicin—ovarian cancer	6.92e-05	0.000492	CcSEcCtD
Carvedilol—Rhinitis—Doxorubicin—ovarian cancer	6.91e-05	0.000491	CcSEcCtD
Carvedilol—Dyspepsia—Docetaxel—ovarian cancer	6.9e-05	0.00049	CcSEcCtD
Carvedilol—Haemorrhage—Doxorubicin—ovarian cancer	6.89e-05	0.000489	CcSEcCtD
Carvedilol—Hypoaesthesia—Doxorubicin—ovarian cancer	6.86e-05	0.000487	CcSEcCtD
Carvedilol—Pharyngitis—Doxorubicin—ovarian cancer	6.84e-05	0.000486	CcSEcCtD
Carvedilol—Decreased appetite—Docetaxel—ovarian cancer	6.82e-05	0.000484	CcSEcCtD
Carvedilol—Hypersensitivity—Paclitaxel—ovarian cancer	6.82e-05	0.000484	CcSEcCtD
Carvedilol—Urinary tract disorder—Doxorubicin—ovarian cancer	6.8e-05	0.000483	CcSEcCtD
Carvedilol—Oedema peripheral—Doxorubicin—ovarian cancer	6.79e-05	0.000482	CcSEcCtD
Carvedilol—Gastrointestinal disorder—Docetaxel—ovarian cancer	6.77e-05	0.000481	CcSEcCtD
Carvedilol—Fatigue—Docetaxel—ovarian cancer	6.76e-05	0.00048	CcSEcCtD
Carvedilol—Angiopathy—Epirubicin—ovarian cancer	6.76e-05	0.00048	CcSEcCtD
Carvedilol—Urethral disorder—Doxorubicin—ovarian cancer	6.75e-05	0.00048	CcSEcCtD
Carvedilol—Immune system disorder—Epirubicin—ovarian cancer	6.73e-05	0.000478	CcSEcCtD
Carvedilol—Mediastinal disorder—Epirubicin—ovarian cancer	6.71e-05	0.000477	CcSEcCtD
Carvedilol—Constipation—Docetaxel—ovarian cancer	6.71e-05	0.000476	CcSEcCtD
Carvedilol—Pain—Docetaxel—ovarian cancer	6.71e-05	0.000476	CcSEcCtD
Carvedilol—Visual impairment—Doxorubicin—ovarian cancer	6.64e-05	0.000472	CcSEcCtD
Carvedilol—Asthenia—Paclitaxel—ovarian cancer	6.64e-05	0.000472	CcSEcCtD
Carvedilol—Alopecia—Epirubicin—ovarian cancer	6.58e-05	0.000467	CcSEcCtD
Carvedilol—Pruritus—Paclitaxel—ovarian cancer	6.55e-05	0.000465	CcSEcCtD
Carvedilol—Erythema multiforme—Doxorubicin—ovarian cancer	6.51e-05	0.000463	CcSEcCtD
Carvedilol—Malnutrition—Epirubicin—ovarian cancer	6.48e-05	0.00046	CcSEcCtD
Carvedilol—Feeling abnormal—Docetaxel—ovarian cancer	6.46e-05	0.000459	CcSEcCtD
Carvedilol—Tinnitus—Doxorubicin—ovarian cancer	6.42e-05	0.000456	CcSEcCtD
Carvedilol—Gastrointestinal pain—Docetaxel—ovarian cancer	6.41e-05	0.000456	CcSEcCtD
Carvedilol—Flatulence—Epirubicin—ovarian cancer	6.39e-05	0.000454	CcSEcCtD
Carvedilol—Tension—Epirubicin—ovarian cancer	6.36e-05	0.000452	CcSEcCtD
Carvedilol—Diarrhoea—Paclitaxel—ovarian cancer	6.33e-05	0.00045	CcSEcCtD
Carvedilol—Nervousness—Epirubicin—ovarian cancer	6.3e-05	0.000447	CcSEcCtD
Carvedilol—Back pain—Epirubicin—ovarian cancer	6.27e-05	0.000445	CcSEcCtD
Carvedilol—Angiopathy—Doxorubicin—ovarian cancer	6.25e-05	0.000444	CcSEcCtD
Carvedilol—Muscle spasms—Epirubicin—ovarian cancer	6.23e-05	0.000443	CcSEcCtD
Carvedilol—Immune system disorder—Doxorubicin—ovarian cancer	6.22e-05	0.000442	CcSEcCtD
Carvedilol—Mediastinal disorder—Doxorubicin—ovarian cancer	6.21e-05	0.000441	CcSEcCtD
Carvedilol—Body temperature increased—Docetaxel—ovarian cancer	6.2e-05	0.00044	CcSEcCtD
Carvedilol—Abdominal pain—Docetaxel—ovarian cancer	6.2e-05	0.00044	CcSEcCtD
Carvedilol—Dizziness—Paclitaxel—ovarian cancer	6.12e-05	0.000435	CcSEcCtD
Carvedilol—Vision blurred—Epirubicin—ovarian cancer	6.11e-05	0.000434	CcSEcCtD
Carvedilol—Alopecia—Doxorubicin—ovarian cancer	6.09e-05	0.000432	CcSEcCtD
Carvedilol—Ill-defined disorder—Epirubicin—ovarian cancer	6.01e-05	0.000427	CcSEcCtD
Carvedilol—Malnutrition—Doxorubicin—ovarian cancer	6e-05	0.000426	CcSEcCtD
Carvedilol—Anaemia—Epirubicin—ovarian cancer	5.99e-05	0.000426	CcSEcCtD
Carvedilol—Flatulence—Doxorubicin—ovarian cancer	5.91e-05	0.00042	CcSEcCtD
Carvedilol—Tension—Doxorubicin—ovarian cancer	5.89e-05	0.000418	CcSEcCtD
Carvedilol—Vomiting—Paclitaxel—ovarian cancer	5.88e-05	0.000418	CcSEcCtD
Carvedilol—Malaise—Epirubicin—ovarian cancer	5.85e-05	0.000415	CcSEcCtD
Carvedilol—Rash—Paclitaxel—ovarian cancer	5.83e-05	0.000414	CcSEcCtD
Carvedilol—Dermatitis—Paclitaxel—ovarian cancer	5.83e-05	0.000414	CcSEcCtD
Carvedilol—Nervousness—Doxorubicin—ovarian cancer	5.83e-05	0.000414	CcSEcCtD
Carvedilol—Vertigo—Epirubicin—ovarian cancer	5.82e-05	0.000414	CcSEcCtD
Carvedilol—Syncope—Epirubicin—ovarian cancer	5.81e-05	0.000413	CcSEcCtD
Carvedilol—Leukopenia—Epirubicin—ovarian cancer	5.8e-05	0.000412	CcSEcCtD
Carvedilol—Back pain—Doxorubicin—ovarian cancer	5.8e-05	0.000412	CcSEcCtD
Carvedilol—Headache—Paclitaxel—ovarian cancer	5.8e-05	0.000412	CcSEcCtD
Carvedilol—Hypersensitivity—Docetaxel—ovarian cancer	5.78e-05	0.00041	CcSEcCtD
Carvedilol—Muscle spasms—Doxorubicin—ovarian cancer	5.77e-05	0.00041	CcSEcCtD
Carvedilol—Palpitations—Epirubicin—ovarian cancer	5.73e-05	0.000407	CcSEcCtD
Carvedilol—Loss of consciousness—Epirubicin—ovarian cancer	5.7e-05	0.000405	CcSEcCtD
Carvedilol—Cough—Epirubicin—ovarian cancer	5.66e-05	0.000402	CcSEcCtD
Carvedilol—Vision blurred—Doxorubicin—ovarian cancer	5.65e-05	0.000401	CcSEcCtD
Carvedilol—ABCB1—lymph node—ovarian cancer	5.63e-05	0.000517	CbGeAlD
Carvedilol—Asthenia—Docetaxel—ovarian cancer	5.63e-05	0.0004	CcSEcCtD
Carvedilol—Convulsion—Epirubicin—ovarian cancer	5.62e-05	0.000399	CcSEcCtD
Carvedilol—Hypertension—Epirubicin—ovarian cancer	5.6e-05	0.000398	CcSEcCtD
Carvedilol—Ill-defined disorder—Doxorubicin—ovarian cancer	5.56e-05	0.000395	CcSEcCtD
Carvedilol—Pruritus—Docetaxel—ovarian cancer	5.55e-05	0.000394	CcSEcCtD
Carvedilol—Anaemia—Doxorubicin—ovarian cancer	5.54e-05	0.000394	CcSEcCtD
Carvedilol—Myalgia—Epirubicin—ovarian cancer	5.52e-05	0.000392	CcSEcCtD
Carvedilol—Chest pain—Epirubicin—ovarian cancer	5.52e-05	0.000392	CcSEcCtD
Carvedilol—Arthralgia—Epirubicin—ovarian cancer	5.52e-05	0.000392	CcSEcCtD
Carvedilol—Nausea—Paclitaxel—ovarian cancer	5.5e-05	0.00039	CcSEcCtD
Carvedilol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	5.48e-05	0.000389	CcSEcCtD
Carvedilol—Discomfort—Epirubicin—ovarian cancer	5.45e-05	0.000387	CcSEcCtD
Carvedilol—Malaise—Doxorubicin—ovarian cancer	5.41e-05	0.000384	CcSEcCtD
Carvedilol—Dry mouth—Epirubicin—ovarian cancer	5.4e-05	0.000383	CcSEcCtD
Carvedilol—Vertigo—Doxorubicin—ovarian cancer	5.39e-05	0.000383	CcSEcCtD
Carvedilol—Syncope—Doxorubicin—ovarian cancer	5.38e-05	0.000382	CcSEcCtD
Carvedilol—Leukopenia—Doxorubicin—ovarian cancer	5.37e-05	0.000381	CcSEcCtD
Carvedilol—Diarrhoea—Docetaxel—ovarian cancer	5.37e-05	0.000381	CcSEcCtD
Carvedilol—Confusional state—Epirubicin—ovarian cancer	5.33e-05	0.000379	CcSEcCtD
Carvedilol—Palpitations—Doxorubicin—ovarian cancer	5.3e-05	0.000376	CcSEcCtD
Carvedilol—Oedema—Epirubicin—ovarian cancer	5.29e-05	0.000376	CcSEcCtD
Carvedilol—Anaphylactic shock—Epirubicin—ovarian cancer	5.29e-05	0.000376	CcSEcCtD
Carvedilol—Loss of consciousness—Doxorubicin—ovarian cancer	5.27e-05	0.000374	CcSEcCtD
Carvedilol—Infection—Epirubicin—ovarian cancer	5.26e-05	0.000373	CcSEcCtD
Carvedilol—Cough—Doxorubicin—ovarian cancer	5.23e-05	0.000372	CcSEcCtD
Carvedilol—Shock—Epirubicin—ovarian cancer	5.2e-05	0.00037	CcSEcCtD
Carvedilol—Convulsion—Doxorubicin—ovarian cancer	5.2e-05	0.000369	CcSEcCtD
Carvedilol—Dizziness—Docetaxel—ovarian cancer	5.19e-05	0.000368	CcSEcCtD
Carvedilol—Thrombocytopenia—Epirubicin—ovarian cancer	5.18e-05	0.000368	CcSEcCtD
Carvedilol—Hypertension—Doxorubicin—ovarian cancer	5.18e-05	0.000368	CcSEcCtD
Carvedilol—Tachycardia—Epirubicin—ovarian cancer	5.16e-05	0.000367	CcSEcCtD
Carvedilol—Skin disorder—Epirubicin—ovarian cancer	5.14e-05	0.000365	CcSEcCtD
Carvedilol—Hyperhidrosis—Epirubicin—ovarian cancer	5.11e-05	0.000363	CcSEcCtD
Carvedilol—Chest pain—Doxorubicin—ovarian cancer	5.11e-05	0.000363	CcSEcCtD
Carvedilol—Arthralgia—Doxorubicin—ovarian cancer	5.11e-05	0.000363	CcSEcCtD
Carvedilol—Myalgia—Doxorubicin—ovarian cancer	5.11e-05	0.000363	CcSEcCtD
Carvedilol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	5.07e-05	0.00036	CcSEcCtD
Carvedilol—Discomfort—Doxorubicin—ovarian cancer	5.04e-05	0.000358	CcSEcCtD
Carvedilol—Anorexia—Epirubicin—ovarian cancer	5.04e-05	0.000358	CcSEcCtD
Carvedilol—Dry mouth—Doxorubicin—ovarian cancer	4.99e-05	0.000355	CcSEcCtD
Carvedilol—Vomiting—Docetaxel—ovarian cancer	4.99e-05	0.000354	CcSEcCtD
Carvedilol—Rash—Docetaxel—ovarian cancer	4.95e-05	0.000351	CcSEcCtD
Carvedilol—Hypotension—Epirubicin—ovarian cancer	4.94e-05	0.000351	CcSEcCtD
Carvedilol—Dermatitis—Docetaxel—ovarian cancer	4.94e-05	0.000351	CcSEcCtD
Carvedilol—Confusional state—Doxorubicin—ovarian cancer	4.94e-05	0.000351	CcSEcCtD
Carvedilol—Headache—Docetaxel—ovarian cancer	4.91e-05	0.000349	CcSEcCtD
Carvedilol—Oedema—Doxorubicin—ovarian cancer	4.89e-05	0.000348	CcSEcCtD
Carvedilol—Anaphylactic shock—Doxorubicin—ovarian cancer	4.89e-05	0.000348	CcSEcCtD
Carvedilol—Infection—Doxorubicin—ovarian cancer	4.86e-05	0.000345	CcSEcCtD
Carvedilol—Musculoskeletal discomfort—Epirubicin—ovarian cancer	4.82e-05	0.000342	CcSEcCtD
Carvedilol—Shock—Doxorubicin—ovarian cancer	4.82e-05	0.000342	CcSEcCtD
Carvedilol—Thrombocytopenia—Doxorubicin—ovarian cancer	4.79e-05	0.00034	CcSEcCtD
Carvedilol—Insomnia—Epirubicin—ovarian cancer	4.78e-05	0.00034	CcSEcCtD
Carvedilol—Tachycardia—Doxorubicin—ovarian cancer	4.78e-05	0.000339	CcSEcCtD
Carvedilol—Skin disorder—Doxorubicin—ovarian cancer	4.75e-05	0.000338	CcSEcCtD
Carvedilol—Paraesthesia—Epirubicin—ovarian cancer	4.75e-05	0.000337	CcSEcCtD
Carvedilol—Hyperhidrosis—Doxorubicin—ovarian cancer	4.73e-05	0.000336	CcSEcCtD
Carvedilol—Dyspnoea—Epirubicin—ovarian cancer	4.72e-05	0.000335	CcSEcCtD
Carvedilol—Somnolence—Epirubicin—ovarian cancer	4.7e-05	0.000334	CcSEcCtD
Carvedilol—Anorexia—Doxorubicin—ovarian cancer	4.67e-05	0.000331	CcSEcCtD
Carvedilol—Nausea—Docetaxel—ovarian cancer	4.66e-05	0.000331	CcSEcCtD
Carvedilol—Dyspepsia—Epirubicin—ovarian cancer	4.66e-05	0.000331	CcSEcCtD
Carvedilol—Decreased appetite—Epirubicin—ovarian cancer	4.6e-05	0.000327	CcSEcCtD
Carvedilol—Hypotension—Doxorubicin—ovarian cancer	4.57e-05	0.000325	CcSEcCtD
Carvedilol—Gastrointestinal disorder—Epirubicin—ovarian cancer	4.57e-05	0.000324	CcSEcCtD
Carvedilol—Fatigue—Epirubicin—ovarian cancer	4.56e-05	0.000324	CcSEcCtD
Carvedilol—Pain—Epirubicin—ovarian cancer	4.52e-05	0.000321	CcSEcCtD
Carvedilol—Constipation—Epirubicin—ovarian cancer	4.52e-05	0.000321	CcSEcCtD
Carvedilol—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	4.46e-05	0.000317	CcSEcCtD
Carvedilol—Insomnia—Doxorubicin—ovarian cancer	4.43e-05	0.000314	CcSEcCtD
Carvedilol—Paraesthesia—Doxorubicin—ovarian cancer	4.4e-05	0.000312	CcSEcCtD
Carvedilol—Dyspnoea—Doxorubicin—ovarian cancer	4.36e-05	0.00031	CcSEcCtD
Carvedilol—Feeling abnormal—Epirubicin—ovarian cancer	4.36e-05	0.00031	CcSEcCtD
Carvedilol—Somnolence—Doxorubicin—ovarian cancer	4.35e-05	0.000309	CcSEcCtD
Carvedilol—Gastrointestinal pain—Epirubicin—ovarian cancer	4.33e-05	0.000307	CcSEcCtD
Carvedilol—Dyspepsia—Doxorubicin—ovarian cancer	4.31e-05	0.000306	CcSEcCtD
Carvedilol—Decreased appetite—Doxorubicin—ovarian cancer	4.26e-05	0.000302	CcSEcCtD
Carvedilol—Gastrointestinal disorder—Doxorubicin—ovarian cancer	4.23e-05	0.0003	CcSEcCtD
Carvedilol—Fatigue—Doxorubicin—ovarian cancer	4.22e-05	0.0003	CcSEcCtD
Carvedilol—Urticaria—Epirubicin—ovarian cancer	4.2e-05	0.000299	CcSEcCtD
Carvedilol—Pain—Doxorubicin—ovarian cancer	4.19e-05	0.000297	CcSEcCtD
Carvedilol—Constipation—Doxorubicin—ovarian cancer	4.19e-05	0.000297	CcSEcCtD
Carvedilol—Body temperature increased—Epirubicin—ovarian cancer	4.18e-05	0.000297	CcSEcCtD
Carvedilol—Abdominal pain—Epirubicin—ovarian cancer	4.18e-05	0.000297	CcSEcCtD
Carvedilol—Feeling abnormal—Doxorubicin—ovarian cancer	4.03e-05	0.000287	CcSEcCtD
Carvedilol—Gastrointestinal pain—Doxorubicin—ovarian cancer	4e-05	0.000284	CcSEcCtD
Carvedilol—Hypersensitivity—Epirubicin—ovarian cancer	3.9e-05	0.000277	CcSEcCtD
Carvedilol—Urticaria—Doxorubicin—ovarian cancer	3.89e-05	0.000276	CcSEcCtD
Carvedilol—Body temperature increased—Doxorubicin—ovarian cancer	3.87e-05	0.000275	CcSEcCtD
Carvedilol—Abdominal pain—Doxorubicin—ovarian cancer	3.87e-05	0.000275	CcSEcCtD
Carvedilol—Asthenia—Epirubicin—ovarian cancer	3.8e-05	0.00027	CcSEcCtD
Carvedilol—Pruritus—Epirubicin—ovarian cancer	3.74e-05	0.000266	CcSEcCtD
Carvedilol—Diarrhoea—Epirubicin—ovarian cancer	3.62e-05	0.000257	CcSEcCtD
Carvedilol—Hypersensitivity—Doxorubicin—ovarian cancer	3.61e-05	0.000256	CcSEcCtD
Carvedilol—Asthenia—Doxorubicin—ovarian cancer	3.51e-05	0.000249	CcSEcCtD
Carvedilol—Dizziness—Epirubicin—ovarian cancer	3.5e-05	0.000248	CcSEcCtD
Carvedilol—Pruritus—Doxorubicin—ovarian cancer	3.46e-05	0.000246	CcSEcCtD
Carvedilol—Vomiting—Epirubicin—ovarian cancer	3.36e-05	0.000239	CcSEcCtD
Carvedilol—Diarrhoea—Doxorubicin—ovarian cancer	3.35e-05	0.000238	CcSEcCtD
Carvedilol—Rash—Epirubicin—ovarian cancer	3.34e-05	0.000237	CcSEcCtD
Carvedilol—Dermatitis—Epirubicin—ovarian cancer	3.33e-05	0.000237	CcSEcCtD
Carvedilol—Headache—Epirubicin—ovarian cancer	3.31e-05	0.000235	CcSEcCtD
Carvedilol—Dizziness—Doxorubicin—ovarian cancer	3.24e-05	0.00023	CcSEcCtD
Carvedilol—Nausea—Epirubicin—ovarian cancer	3.14e-05	0.000223	CcSEcCtD
Carvedilol—Vomiting—Doxorubicin—ovarian cancer	3.11e-05	0.000221	CcSEcCtD
Carvedilol—Rash—Doxorubicin—ovarian cancer	3.09e-05	0.000219	CcSEcCtD
Carvedilol—Dermatitis—Doxorubicin—ovarian cancer	3.08e-05	0.000219	CcSEcCtD
Carvedilol—Headache—Doxorubicin—ovarian cancer	3.07e-05	0.000218	CcSEcCtD
Carvedilol—Nausea—Doxorubicin—ovarian cancer	2.91e-05	0.000207	CcSEcCtD
Carvedilol—ADRA1A—Signaling by GPCR—KRAS—ovarian cancer	2.83e-06	2.61e-05	CbGpPWpGaD
Carvedilol—ADRB2—GPCR downstream signaling—AKT1—ovarian cancer	2.83e-06	2.61e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—IL6—ovarian cancer	2.83e-06	2.61e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—IL6—ovarian cancer	2.82e-06	2.6e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—CASP3—ovarian cancer	2.8e-06	2.58e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—PIK3CB—ovarian cancer	2.8e-06	2.58e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—ABCB1—ovarian cancer	2.8e-06	2.58e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—IL2—ovarian cancer	2.8e-06	2.58e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—CCND1—ovarian cancer	2.79e-06	2.57e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—MAPK1—ovarian cancer	2.79e-06	2.57e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—IL6—ovarian cancer	2.79e-06	2.57e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—EGFR—ovarian cancer	2.79e-06	2.57e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—PIK3CD—ovarian cancer	2.78e-06	2.56e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—CAV1—ovarian cancer	2.78e-06	2.56e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—CXCL8—ovarian cancer	2.77e-06	2.55e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—CCND1—ovarian cancer	2.76e-06	2.55e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—CTNNB1—ovarian cancer	2.76e-06	2.55e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—HRAS—ovarian cancer	2.75e-06	2.54e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—TYMS—ovarian cancer	2.75e-06	2.53e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—CTNNB1—ovarian cancer	2.74e-06	2.52e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—SLC2A1—ovarian cancer	2.74e-06	2.52e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—CCND1—ovarian cancer	2.73e-06	2.52e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—CXCL8—ovarian cancer	2.73e-06	2.51e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—HRAS—ovarian cancer	2.71e-06	2.5e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—MMP9—ovarian cancer	2.71e-06	2.5e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—CDKN1B—ovarian cancer	2.71e-06	2.49e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—CTNNB1—ovarian cancer	2.7e-06	2.49e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—PTEN—ovarian cancer	2.69e-06	2.48e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—PIK3CD—ovarian cancer	2.69e-06	2.48e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—MMP9—ovarian cancer	2.68e-06	2.47e-05	CbGpPWpGaD
Carvedilol—ADRA2C—GPCR downstream signaling—AKT1—ovarian cancer	2.68e-06	2.47e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—VEGFA—ovarian cancer	2.67e-06	2.46e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—PTEN—ovarian cancer	2.67e-06	2.46e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—CDKN1B—ovarian cancer	2.66e-06	2.46e-05	CbGpPWpGaD
Carvedilol—ADRA2A—GPCR downstream signaling—PIK3CA—ovarian cancer	2.66e-06	2.45e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—CASP3—ovarian cancer	2.65e-06	2.45e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—MMP9—ovarian cancer	2.65e-06	2.44e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—IL2—ovarian cancer	2.65e-06	2.44e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—STAT3—ovarian cancer	2.64e-06	2.44e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—NRAS—ovarian cancer	2.64e-06	2.43e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—IL6—ovarian cancer	2.64e-06	2.43e-05	CbGpPWpGaD
Carvedilol—ADRA1B—GPCR downstream signaling—AKT1—ovarian cancer	2.64e-06	2.43e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—PTEN—ovarian cancer	2.63e-06	2.43e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—KRAS—ovarian cancer	2.63e-06	2.43e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—AKT1—ovarian cancer	2.63e-06	2.42e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—CYP1B1—ovarian cancer	2.62e-06	2.42e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—CAV1—ovarian cancer	2.62e-06	2.41e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—AKT1—ovarian cancer	2.62e-06	2.41e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—CASP3—ovarian cancer	2.61e-06	2.41e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—AKT1—ovarian cancer	2.61e-06	2.4e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—IL2—ovarian cancer	2.61e-06	2.4e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—AKT1—ovarian cancer	2.6e-06	2.4e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—PIK3CA—ovarian cancer	2.6e-06	2.4e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—IL6—ovarian cancer	2.59e-06	2.39e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—CAV1—ovarian cancer	2.59e-06	2.39e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—CCND1—ovarian cancer	2.58e-06	2.38e-05	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—PIK3CB—ovarian cancer	2.57e-06	2.37e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—AKT1—ovarian cancer	2.57e-06	2.37e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—CTNNB1—ovarian cancer	2.56e-06	2.36e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—ERBB2—ovarian cancer	2.56e-06	2.35e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—CCND1—ovarian cancer	2.54e-06	2.34e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—PIK3CG—ovarian cancer	2.53e-06	2.33e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—MAPK3—ovarian cancer	2.53e-06	2.33e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—PIK3CB—ovarian cancer	2.52e-06	2.32e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—MTOR—ovarian cancer	2.52e-06	2.32e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—CTNNB1—ovarian cancer	2.52e-06	2.32e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—MMP9—ovarian cancer	2.51e-06	2.31e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—PTEN—ovarian cancer	2.49e-06	2.3e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	2.48e-06	2.28e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—MMP9—ovarian cancer	2.47e-06	2.27e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—MYC—ovarian cancer	2.46e-06	2.26e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—PTEN—ovarian cancer	2.45e-06	2.26e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—VEGFA—ovarian cancer	2.43e-06	2.24e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—AKT1—ovarian cancer	2.43e-06	2.24e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—PIK3CB—ovarian cancer	2.43e-06	2.24e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—CXCL8—ovarian cancer	2.42e-06	2.23e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—PTEN—ovarian cancer	2.42e-06	2.23e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—PIK3CA—ovarian cancer	2.42e-06	2.23e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—VEGFA—ovarian cancer	2.41e-06	2.22e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—STAT3—ovarian cancer	2.41e-06	2.22e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—HRAS—ovarian cancer	2.41e-06	2.22e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—MAPK1—ovarian cancer	2.4e-06	2.21e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—NRAS—ovarian cancer	2.4e-06	2.21e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—EGFR—ovarian cancer	2.4e-06	2.21e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—AKT1—ovarian cancer	2.39e-06	2.21e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—STAT3—ovarian cancer	2.39e-06	2.2e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—PIK3CG—ovarian cancer	2.38e-06	2.2e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—NRAS—ovarian cancer	2.38e-06	2.19e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—VEGFA—ovarian cancer	2.38e-06	2.19e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—ERBB2—ovarian cancer	2.37e-06	2.19e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—CDKN1B—ovarian cancer	2.37e-06	2.18e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—PIK3CG—ovarian cancer	2.36e-06	2.18e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—STAT3—ovarian cancer	2.36e-06	2.17e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—NRAS—ovarian cancer	2.35e-06	2.17e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—MTOR—ovarian cancer	2.34e-06	2.16e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—PIK3CB—ovarian cancer	2.34e-06	2.16e-05	CbGpPWpGaD
Carvedilol—ADRA1A—GPCR downstream signaling—AKT1—ovarian cancer	2.34e-06	2.16e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	2.33e-06	2.15e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—CASP3—ovarian cancer	2.32e-06	2.14e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—IL2—ovarian cancer	2.32e-06	2.13e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—IL6—ovarian cancer	2.3e-06	2.12e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—MAPK3—ovarian cancer	2.3e-06	2.12e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—MAPK3—ovarian cancer	2.28e-06	2.1e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—KRAS—ovarian cancer	2.27e-06	2.09e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—CCND1—ovarian cancer	2.26e-06	2.08e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—CXCL8—ovarian cancer	2.25e-06	2.07e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—VEGFA—ovarian cancer	2.25e-06	2.07e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—MAPK3—ovarian cancer	2.25e-06	2.07e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—MYC—ovarian cancer	2.24e-06	2.06e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—HRAS—ovarian cancer	2.24e-06	2.06e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—CTNNB1—ovarian cancer	2.24e-06	2.06e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—STAT3—ovarian cancer	2.23e-06	2.05e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—NRAS—ovarian cancer	2.22e-06	2.05e-05	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—PTEN—ovarian cancer	2.22e-06	2.05e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—PIK3CD—ovarian cancer	2.22e-06	2.05e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—MYC—ovarian cancer	2.22e-06	2.04e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—CAV1—ovarian cancer	2.22e-06	2.04e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—VEGFA—ovarian cancer	2.22e-06	2.04e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—CDKN1B—ovarian cancer	2.2e-06	2.03e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—STAT3—ovarian cancer	2.19e-06	2.02e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—MMP9—ovarian cancer	2.19e-06	2.02e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—MAPK1—ovarian cancer	2.19e-06	2.02e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—MYC—ovarian cancer	2.19e-06	2.02e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—EGFR—ovarian cancer	2.19e-06	2.02e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—NRAS—ovarian cancer	2.19e-06	2.02e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—PTEN—ovarian cancer	2.18e-06	2.01e-05	CbGpPWpGaD
Carvedilol—ADRA2A—GPCR downstream signaling—AKT1—ovarian cancer	2.18e-06	2e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—MAPK1—ovarian cancer	2.17e-06	2e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—EGFR—ovarian cancer	2.17e-06	2e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—ABCB1—ovarian cancer	2.16e-06	1.99e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—CASP3—ovarian cancer	2.16e-06	1.99e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—IL2—ovarian cancer	2.15e-06	1.98e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—MAPK1—ovarian cancer	2.14e-06	1.97e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—EGFR—ovarian cancer	2.14e-06	1.97e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—IL6—ovarian cancer	2.14e-06	1.97e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—MAPK3—ovarian cancer	2.13e-06	1.96e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—AKT1—ovarian cancer	2.13e-06	1.96e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—TYMS—ovarian cancer	2.12e-06	1.96e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	2.12e-06	1.95e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—PIK3CA—ovarian cancer	2.1e-06	1.94e-05	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—PIK3CA—ovarian cancer	2.1e-06	1.93e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—CCND1—ovarian cancer	2.1e-06	1.93e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—PTEN—ovarian cancer	2.1e-06	1.93e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—MAPK3—ovarian cancer	2.1e-06	1.93e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—PIK3CD—ovarian cancer	2.09e-06	1.93e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—PIK3CA—ovarian cancer	2.09e-06	1.92e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—CTNNB1—ovarian cancer	2.08e-06	1.91e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—PIK3CD—ovarian cancer	2.08e-06	1.91e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—MYC—ovarian cancer	2.07e-06	1.91e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—KRAS—ovarian cancer	2.07e-06	1.91e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—KRAS—ovarian cancer	2.05e-06	1.89e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—MYC—ovarian cancer	2.04e-06	1.88e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—MMP9—ovarian cancer	2.04e-06	1.88e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—MAPK1—ovarian cancer	2.03e-06	1.87e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—EGFR—ovarian cancer	2.03e-06	1.87e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—PTEN—ovarian cancer	2.02e-06	1.87e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—KRAS—ovarian cancer	2.02e-06	1.86e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—PIK3CG—ovarian cancer	2.02e-06	1.86e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—TP53—ovarian cancer	2.02e-06	1.86e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—MAPK1—ovarian cancer	1.99e-06	1.84e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—EGFR—ovarian cancer	1.99e-06	1.84e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—AKT1—ovarian cancer	1.98e-06	1.82e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—VEGFA—ovarian cancer	1.97e-06	1.81e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—STAT3—ovarian cancer	1.95e-06	1.8e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—NRAS—ovarian cancer	1.94e-06	1.79e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—PIK3CB—ovarian cancer	1.94e-06	1.79e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—HRAS—ovarian cancer	1.93e-06	1.78e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—KRAS—ovarian cancer	1.91e-06	1.76e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—PIK3CA—ovarian cancer	1.9e-06	1.75e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—KRAS—ovarian cancer	1.88e-06	1.74e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—PIK3CA—ovarian cancer	1.88e-06	1.73e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—MAPK3—ovarian cancer	1.86e-06	1.72e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—PIK3CA—ovarian cancer	1.86e-06	1.71e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—IL6—ovarian cancer	1.85e-06	1.7e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—TP53—ovarian cancer	1.84e-06	1.69e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—VEGFA—ovarian cancer	1.83e-06	1.69e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—PIK3CB—ovarian cancer	1.83e-06	1.68e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—TP53—ovarian cancer	1.82e-06	1.68e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—MYC—ovarian cancer	1.81e-06	1.67e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—STAT3—ovarian cancer	1.81e-06	1.67e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—PIK3CB—ovarian cancer	1.81e-06	1.67e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—NRAS—ovarian cancer	1.81e-06	1.66e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—TP53—ovarian cancer	1.8e-06	1.66e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—PIK3CD—ovarian cancer	1.77e-06	1.64e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—MAPK1—ovarian cancer	1.77e-06	1.63e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—EGFR—ovarian cancer	1.77e-06	1.63e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—PIK3CA—ovarian cancer	1.76e-06	1.62e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—HRAS—ovarian cancer	1.76e-06	1.62e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—HRAS—ovarian cancer	1.74e-06	1.61e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—PIK3CA—ovarian cancer	1.73e-06	1.59e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—MAPK3—ovarian cancer	1.73e-06	1.59e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—HRAS—ovarian cancer	1.72e-06	1.58e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—AKT1—ovarian cancer	1.72e-06	1.58e-05	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—AKT1—ovarian cancer	1.71e-06	1.58e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—CAV1—ovarian cancer	1.71e-06	1.58e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—PIK3CA—ovarian cancer	1.71e-06	1.57e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—AKT1—ovarian cancer	1.7e-06	1.57e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—TP53—ovarian cancer	1.7e-06	1.57e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—MYC—ovarian cancer	1.68e-06	1.55e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—IL6—ovarian cancer	1.68e-06	1.55e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—PTEN—ovarian cancer	1.67e-06	1.54e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—TP53—ovarian cancer	1.67e-06	1.54e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—KRAS—ovarian cancer	1.67e-06	1.54e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—IL6—ovarian cancer	1.67e-06	1.54e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—MAPK1—ovarian cancer	1.65e-06	1.52e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—IL6—ovarian cancer	1.65e-06	1.52e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—EGFR—ovarian cancer	1.65e-06	1.52e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—HRAS—ovarian cancer	1.63e-06	1.5e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—HRAS—ovarian cancer	1.6e-06	1.48e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—PTEN—ovarian cancer	1.58e-06	1.45e-05	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—PIK3CA—ovarian cancer	1.57e-06	1.45e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—PTEN—ovarian cancer	1.56e-06	1.44e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—PIK3CG—ovarian cancer	1.56e-06	1.44e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—IL6—ovarian cancer	1.56e-06	1.43e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—KRAS—ovarian cancer	1.55e-06	1.43e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—AKT1—ovarian cancer	1.55e-06	1.43e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—PIK3CB—ovarian cancer	1.55e-06	1.43e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—AKT1—ovarian cancer	1.54e-06	1.42e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—PIK3CA—ovarian cancer	1.54e-06	1.42e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—IL6—ovarian cancer	1.53e-06	1.41e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—AKT1—ovarian cancer	1.52e-06	1.4e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—TP53—ovarian cancer	1.49e-06	1.37e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—PIK3CA—ovarian cancer	1.48e-06	1.36e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—AKT1—ovarian cancer	1.44e-06	1.32e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—PIK3CA—ovarian cancer	1.43e-06	1.32e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—HRAS—ovarian cancer	1.42e-06	1.31e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—AKT1—ovarian cancer	1.41e-06	1.3e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—AKT1—ovarian cancer	1.4e-06	1.29e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—TP53—ovarian cancer	1.38e-06	1.27e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—PIK3CD—ovarian cancer	1.37e-06	1.26e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—IL6—ovarian cancer	1.36e-06	1.25e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—PTEN—ovarian cancer	1.34e-06	1.23e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—HRAS—ovarian cancer	1.32e-06	1.22e-05	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—AKT1—ovarian cancer	1.28e-06	1.18e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—IL6—ovarian cancer	1.26e-06	1.17e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—AKT1—ovarian cancer	1.26e-06	1.16e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—AKT1—ovarian cancer	1.21e-06	1.11e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—PIK3CB—ovarian cancer	1.19e-06	1.1e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—PIK3CA—ovarian cancer	1.18e-06	1.09e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—AKT1—ovarian cancer	1.17e-06	1.08e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—PIK3CA—ovarian cancer	1.11e-06	1.03e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—PIK3CA—ovarian cancer	1.1e-06	1.02e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—PTEN—ovarian cancer	1.03e-06	9.51e-06	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—AKT1—ovarian cancer	9.65e-07	8.89e-06	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—PIK3CA—ovarian cancer	9.43e-07	8.69e-06	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—AKT1—ovarian cancer	9.09e-07	8.38e-06	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—AKT1—ovarian cancer	9.01e-07	8.31e-06	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—AKT1—ovarian cancer	7.7e-07	7.1e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—PIK3CA—ovarian cancer	7.28e-07	6.71e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—AKT1—ovarian cancer	5.95e-07	5.48e-06	CbGpPWpGaD
